Cysteine boosters the evolutionary adaptation to CoCl2 mimicked hypoxia conditions, favouring carboplatin resistance in ovarian cancer

Detalhes bibliográficos
Autor(a) principal: Nunes, Sofia C.
Data de Publicação: 2018
Outros Autores: Lopes-Coelho, Filipa, Gouveia-Fernandes, Sofia, Ramos, Cristiano, Pereira, Sofia A., Serpa, Jacinta
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
DOI: 10.1186/s12862-018-1214-1
Texto Completo: https://doi.org/10.1186/s12862-018-1214-1
Resumo: The authors would like to acknowledge the Instituto Português de Oncologia de Lisboa Francisco Gentil (IPOLFG) for partially funding the project. The study was also funded by Projecto TVI. This research was supported by Fundação para a Ciência e Tecnologia (FCT) (PhD ProRegeM program, PD/BD/105893/2014) and iNOVA4Health.
id RCAP_e5c36ef3c3b882f98e67ef1bc57deb20
oai_identifier_str oai:run.unl.pt:10362/41064
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Cysteine boosters the evolutionary adaptation to CoCl2 mimicked hypoxia conditions, favouring carboplatin resistance in ovarian cancerChemoresistanceCysteineEvolutionary trade-offHypoxiaMetabolic selectionOvarian cancerEcology, Evolution, Behavior and SystematicsSDG 3 - Good Health and Well-beingThe authors would like to acknowledge the Instituto Português de Oncologia de Lisboa Francisco Gentil (IPOLFG) for partially funding the project. The study was also funded by Projecto TVI. This research was supported by Fundação para a Ciência e Tecnologia (FCT) (PhD ProRegeM program, PD/BD/105893/2014) and iNOVA4Health.Background: Ovarian cancer is the second most common gynaecologic malignancy and the most common cause of death from gynaecologic cancer, especially due to diagnosis at an advanced stage, when a cure is rare. As ovarian tumour grows, cancer cells are exposed to regions of hypoxia. Hypoxia is known to be partially responsible for tumour progression, metastasis and resistance to therapies. These suggest that hypoxia entails a selective pressure in which the adapted cells not only have a fitness increase under the selective environment, but also in non-selective adverse environments. In here, we used two different ovarian cancer cell lines - serous carcinoma (OVCAR3) and clear cell carcinoma (ES2) - in order to address the effect of cancer cells selection under normoxia and hypoxia mimicked by cobalt chloride on the evolutionary outcome of cancer cells. Results: Our results showed that the adaptation to normoxia and CoCl2 mimicked hypoxia leads cells to display opposite strategies. Whereas cells adapted to CoCl2 mimicked hypoxia conditions tend to proliferate less but present increased survival in adverse environments, cells adapted to normoxia proliferate rapidly but at the cost of increased mortality in adverse environments. Moreover, results suggest that cysteine allows a quicker response and adaptation to hypoxic conditions that, in turn, are capable of driving chemoresistance. Conclusions: We showed that cysteine impacts the adaptation of cancer cells to a CoCl2 mimicked hypoxic environment thus contributing for hypoxia-drived platinum-based chemotherapeutic agents' resistance, allowing the selection of more aggressive phenotypes. These observations support a role of cysteine in cancer progression, recurrence and chemoresistance.NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)Centro de Estudos de Doenças Crónicas (CEDOC)RUNNunes, Sofia C.Lopes-Coelho, FilipaGouveia-Fernandes, SofiaRamos, CristianoPereira, Sofia A.Serpa, Jacinta2018-07-06T22:11:02Z2018-06-192018-06-19T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://doi.org/10.1186/s12862-018-1214-1eng1471-2148PURE: 5358085http://www.scopus.com/inward/record.url?scp=85049032652&partnerID=8YFLogxKhttps://doi.org/10.1186/s12862-018-1214-1info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-10-21T01:35:57Zoai:run.unl.pt:10362/41064Portal AgregadorONGhttps://www.rcaap.pt/oai/openairemluisa.alvim@gmail.comopendoar:71602024-10-21T01:35:57Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Cysteine boosters the evolutionary adaptation to CoCl2 mimicked hypoxia conditions, favouring carboplatin resistance in ovarian cancer
title Cysteine boosters the evolutionary adaptation to CoCl2 mimicked hypoxia conditions, favouring carboplatin resistance in ovarian cancer
spellingShingle Cysteine boosters the evolutionary adaptation to CoCl2 mimicked hypoxia conditions, favouring carboplatin resistance in ovarian cancer
Cysteine boosters the evolutionary adaptation to CoCl2 mimicked hypoxia conditions, favouring carboplatin resistance in ovarian cancer
Nunes, Sofia C.
Chemoresistance
Cysteine
Evolutionary trade-off
Hypoxia
Metabolic selection
Ovarian cancer
Ecology, Evolution, Behavior and Systematics
SDG 3 - Good Health and Well-being
Nunes, Sofia C.
Chemoresistance
Cysteine
Evolutionary trade-off
Hypoxia
Metabolic selection
Ovarian cancer
Ecology, Evolution, Behavior and Systematics
SDG 3 - Good Health and Well-being
title_short Cysteine boosters the evolutionary adaptation to CoCl2 mimicked hypoxia conditions, favouring carboplatin resistance in ovarian cancer
title_full Cysteine boosters the evolutionary adaptation to CoCl2 mimicked hypoxia conditions, favouring carboplatin resistance in ovarian cancer
title_fullStr Cysteine boosters the evolutionary adaptation to CoCl2 mimicked hypoxia conditions, favouring carboplatin resistance in ovarian cancer
Cysteine boosters the evolutionary adaptation to CoCl2 mimicked hypoxia conditions, favouring carboplatin resistance in ovarian cancer
title_full_unstemmed Cysteine boosters the evolutionary adaptation to CoCl2 mimicked hypoxia conditions, favouring carboplatin resistance in ovarian cancer
Cysteine boosters the evolutionary adaptation to CoCl2 mimicked hypoxia conditions, favouring carboplatin resistance in ovarian cancer
title_sort Cysteine boosters the evolutionary adaptation to CoCl2 mimicked hypoxia conditions, favouring carboplatin resistance in ovarian cancer
author Nunes, Sofia C.
author_facet Nunes, Sofia C.
Nunes, Sofia C.
Lopes-Coelho, Filipa
Gouveia-Fernandes, Sofia
Ramos, Cristiano
Pereira, Sofia A.
Serpa, Jacinta
Lopes-Coelho, Filipa
Gouveia-Fernandes, Sofia
Ramos, Cristiano
Pereira, Sofia A.
Serpa, Jacinta
author_role author
author2 Lopes-Coelho, Filipa
Gouveia-Fernandes, Sofia
Ramos, Cristiano
Pereira, Sofia A.
Serpa, Jacinta
author2_role author
author
author
author
author
dc.contributor.none.fl_str_mv NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
Centro de Estudos de Doenças Crónicas (CEDOC)
RUN
dc.contributor.author.fl_str_mv Nunes, Sofia C.
Lopes-Coelho, Filipa
Gouveia-Fernandes, Sofia
Ramos, Cristiano
Pereira, Sofia A.
Serpa, Jacinta
dc.subject.por.fl_str_mv Chemoresistance
Cysteine
Evolutionary trade-off
Hypoxia
Metabolic selection
Ovarian cancer
Ecology, Evolution, Behavior and Systematics
SDG 3 - Good Health and Well-being
topic Chemoresistance
Cysteine
Evolutionary trade-off
Hypoxia
Metabolic selection
Ovarian cancer
Ecology, Evolution, Behavior and Systematics
SDG 3 - Good Health and Well-being
description The authors would like to acknowledge the Instituto Português de Oncologia de Lisboa Francisco Gentil (IPOLFG) for partially funding the project. The study was also funded by Projecto TVI. This research was supported by Fundação para a Ciência e Tecnologia (FCT) (PhD ProRegeM program, PD/BD/105893/2014) and iNOVA4Health.
publishDate 2018
dc.date.none.fl_str_mv 2018-07-06T22:11:02Z
2018-06-19
2018-06-19T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://doi.org/10.1186/s12862-018-1214-1
url https://doi.org/10.1186/s12862-018-1214-1
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 1471-2148
PURE: 5358085
http://www.scopus.com/inward/record.url?scp=85049032652&partnerID=8YFLogxK
https://doi.org/10.1186/s12862-018-1214-1
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv mluisa.alvim@gmail.com
_version_ 1822227518603657216
dc.identifier.doi.none.fl_str_mv 10.1186/s12862-018-1214-1

Registros relacionados